Georgia's Online Cancer Information Center

Melanoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Melanoma
Cancer Type = Melanoma
There are currently 12 active Melanoma clinical trials in Georgia.
1.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCT ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
2.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03635983
Protocol IDs
CA045-001
NCI-2018-02224
17-214-08
2018-001423-40
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
6.
NCORP Trial
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03698019
Protocol IDs
S1801
S1801
NCI-2018-02107
Treatment Sites (1)
7.
A Randomized Phase 2 Study of Rituxan Hycela in Patients with Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade with Nivolumab and Ipilimumab
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03719131
Protocol IDs
Winship4457-18
NCI-2018-01804
IRB00105605
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
Phase I / II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
Pilot Integrated Biomarker Study of VX15 / 2503 in Combination with Ipilimumab or Nivolumab in Patients with Resectable Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03769155
Protocol IDs
Winship4400-18
NCI-2018-01229
IRB00104273
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
NCORP Trial
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Cancer Type
Melanoma
NCT ID
NCT02339571
Protocol IDs
EA6141
NCI-2014-02674
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofitthat leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.